Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224213181> ?p ?o ?g. }
- W4224213181 endingPage "946" @default.
- W4224213181 startingPage "946" @default.
- W4224213181 abstract "Background: PSMA-based alpha therapy using 225Ac-PSMA-I&T provides treatment for metastatic castration-resistant prostate cancer (mCRPC), even after the failure of 177Lu-PSMA radioligand therapy (RLT). In clinical routine, the total tumor volume (TTV) on PSMA PET impacts therapy outcomes and plays an increasing role in mCRPC patients. Hence, we aimed to assess TTV and its changes during 225Ac-PSMA-I&T RLT. Methods: mCRPC patients undergoing RLT with 225Ac-PSMA-I&T with available 18F-PSMA-1007 PET/CT prior to therapy initiation were included. TTV was assessed in all patients using established cut-off values. Image derived, clinical and biochemistry parameters (PSA, LDH, AP, pain score) were analyzed prior to and after two cycles of 225Ac-PSMA. Changes in TTV and further parameters were directly compared and then correlated with established response criteria, such as RECIST 1.1 or mPERCIST. Results: 13 mCRPC patients were included. The median overall survival (OS) was 10 months. Prior to 225Ac-PSMA RLT, there was no significant correlation between TTV with other clinical parameters (p > 0.05 each). Between short-term survivors (STS, <10 months OS) and long-term survivors (LTS, ≥10 months OS), TTV and PSA were comparable (p = 0.592 & p = 0.286, respectively), whereas AP was significantly lower in the LTS (p = 0.029). A total of 7/13 patients completed two cycles and underwent a follow-up 18F-PSMA-1007 PET/CT. Among these patients, there was a significant decrease in TTV (median 835 vs. 201 mL, p = 0.028) and PSA (median 687 ng/dL vs. 178 ng/dL, p = 0.018) after two cycles of 225Ac-PSMA RLT. Here, percentage changes of TTV after two cycles showed no direct correlation to all other clinical parameters (p > 0.05 each). In two patients, new PET-avid lesions were detected on 18F-PSMA-1007 PET/CT. However, TTV and PSA were decreasing or stable. Conclusion: PET-derived assessment of TTV is an easily applicable imaging biomarker independent of other established parameters prior to 225Ac-PSMA RLT in these preliminary follow-up data. Even after the failure of 177Lu-PSMA, patients with extensive TTV seem to profit from RLT. All but one patient who was eligible for ≥2 cycles of 225Ac-PSMA-RLT demonstrated drastic TTV decreases without direct correlation to other biomarkers, such as serum PSA changes. Changes in TTV might hence improve the response assessment compared to standard classifiers by reflecting the current tumor load independent of the occurrence of new lesions." @default.
- W4224213181 created "2022-04-26" @default.
- W4224213181 creator A5002308372 @default.
- W4224213181 creator A5004142945 @default.
- W4224213181 creator A5004272744 @default.
- W4224213181 creator A5007901172 @default.
- W4224213181 creator A5025837673 @default.
- W4224213181 creator A5037412930 @default.
- W4224213181 creator A5041891850 @default.
- W4224213181 creator A5045556632 @default.
- W4224213181 creator A5045885487 @default.
- W4224213181 creator A5047813770 @default.
- W4224213181 creator A5053799104 @default.
- W4224213181 creator A5057027148 @default.
- W4224213181 creator A5057320214 @default.
- W4224213181 creator A5057700552 @default.
- W4224213181 creator A5058812626 @default.
- W4224213181 creator A5063796179 @default.
- W4224213181 creator A5066330818 @default.
- W4224213181 creator A5068286198 @default.
- W4224213181 creator A5068808600 @default.
- W4224213181 creator A5073170413 @default.
- W4224213181 creator A5091658189 @default.
- W4224213181 date "2022-04-20" @default.
- W4224213181 modified "2023-10-12" @default.
- W4224213181 title "Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac-PSMA-I&T" @default.
- W4224213181 cites W2019607817 @default.
- W4224213181 cites W2054082787 @default.
- W4224213181 cites W2071433338 @default.
- W4224213181 cites W2330216383 @default.
- W4224213181 cites W2532226140 @default.
- W4224213181 cites W2541665535 @default.
- W4224213181 cites W2590836295 @default.
- W4224213181 cites W2606187374 @default.
- W4224213181 cites W2768562204 @default.
- W4224213181 cites W2801867624 @default.
- W4224213181 cites W2808859772 @default.
- W4224213181 cites W2898151911 @default.
- W4224213181 cites W2974038447 @default.
- W4224213181 cites W2991821398 @default.
- W4224213181 cites W2995200366 @default.
- W4224213181 cites W3000208382 @default.
- W4224213181 cites W3010388685 @default.
- W4224213181 cites W3035356494 @default.
- W4224213181 cites W3040491196 @default.
- W4224213181 cites W3088497176 @default.
- W4224213181 cites W3089634467 @default.
- W4224213181 cites W3112030517 @default.
- W4224213181 cites W3131801237 @default.
- W4224213181 cites W3139391511 @default.
- W4224213181 cites W3162340133 @default.
- W4224213181 cites W3165104578 @default.
- W4224213181 cites W3172086766 @default.
- W4224213181 cites W3174011337 @default.
- W4224213181 cites W3176208875 @default.
- W4224213181 cites W3185362658 @default.
- W4224213181 cites W3186934955 @default.
- W4224213181 cites W3195596495 @default.
- W4224213181 cites W4200227314 @default.
- W4224213181 cites W4200433802 @default.
- W4224213181 cites W4213004412 @default.
- W4224213181 cites W4225792535 @default.
- W4224213181 cites W4246514338 @default.
- W4224213181 doi "https://doi.org/10.3390/biomedicines10050946" @default.
- W4224213181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35625683" @default.
- W4224213181 hasPublicationYear "2022" @default.
- W4224213181 type Work @default.
- W4224213181 citedByCount "5" @default.
- W4224213181 countsByYear W42242131812023 @default.
- W4224213181 crossrefType "journal-article" @default.
- W4224213181 hasAuthorship W4224213181A5002308372 @default.
- W4224213181 hasAuthorship W4224213181A5004142945 @default.
- W4224213181 hasAuthorship W4224213181A5004272744 @default.
- W4224213181 hasAuthorship W4224213181A5007901172 @default.
- W4224213181 hasAuthorship W4224213181A5025837673 @default.
- W4224213181 hasAuthorship W4224213181A5037412930 @default.
- W4224213181 hasAuthorship W4224213181A5041891850 @default.
- W4224213181 hasAuthorship W4224213181A5045556632 @default.
- W4224213181 hasAuthorship W4224213181A5045885487 @default.
- W4224213181 hasAuthorship W4224213181A5047813770 @default.
- W4224213181 hasAuthorship W4224213181A5053799104 @default.
- W4224213181 hasAuthorship W4224213181A5057027148 @default.
- W4224213181 hasAuthorship W4224213181A5057320214 @default.
- W4224213181 hasAuthorship W4224213181A5057700552 @default.
- W4224213181 hasAuthorship W4224213181A5058812626 @default.
- W4224213181 hasAuthorship W4224213181A5063796179 @default.
- W4224213181 hasAuthorship W4224213181A5066330818 @default.
- W4224213181 hasAuthorship W4224213181A5068286198 @default.
- W4224213181 hasAuthorship W4224213181A5068808600 @default.
- W4224213181 hasAuthorship W4224213181A5073170413 @default.
- W4224213181 hasAuthorship W4224213181A5091658189 @default.
- W4224213181 hasBestOaLocation W42242131811 @default.
- W4224213181 hasConcept C121608353 @default.
- W4224213181 hasConcept C126322002 @default.
- W4224213181 hasConcept C126894567 @default.
- W4224213181 hasConcept C185592680 @default.
- W4224213181 hasConcept C2780192828 @default.
- W4224213181 hasConcept C2781197716 @default.